Top news of the week: 09.06.2020.
#Biotech #COVID19 #IPOs #NASDAQ #StockMarket #China
Startups
"It just means to me that people continue to see this sector as one that's worthy of investing and that you see good returns."
#Biotech #COVID19 #IPOs #StockMarket #NASDAQ
https://t.co/83bSWYn4h4
OpenBiotech IPOs near last year's pace, despite COVID-19 pandemic
A successful IPO from Pliant Therapeutics is the first of five potential offerings by biotechs this week, suggesting activity is picking up following earlier coronavirus-related disruption.
China’s biggest-ever Nasdaq biotech IPO comes at an awkward time https://t.co/ao1P8ET7tt Legend via @damiangarde
OpenChina’s biggest-ever Nasdaq biotech IPO comes at an awkward time
Legend’s Wall Street success arrives as a bipartisan group of lawmakers is pushing a bill that could force it and other companies off U.S. exchanges.
3 months after its B round, Akouos files an IPO to the tune of $100M https://t.co/L4SWobXXTU https://t.co/qy8DMfYHRD
Open3 months after its B round, Akouos files an IPO to the tune of $100M
Boston-based hearing loss gene therapy biotech Akouos is gunning for a $100 million IPO amid a near invulnerable market for public-seeking biotechs.
Moderna hires new CFO amid race to develop coronavirus treatment
https://t.co/gkaG2B74Lc https://t.co/b0poWjJfGo
OpenModerna Hires New CFO Amid Race To Develop Coronavirus Treatment
Biotech company Moderna, which is among the leaders in the race to develop a coronavirus vaccine, on Thursday named a sector veteran its new finance chief, as it gears up to launch ...
In conversation with Tom Lynch, president and director of Fred Hutchinson Cancer Research Center https://t.co/RAS36S6u9L https://t.co/sY3IGT7Jvx
OpenIn conversation with Tom Lynch, president and director of Fred Hutchinson Cancer Research Center
From chief scientific officer of Bristol Myers Squibb (back when it still had a hyphen) to running one of the biggest cancer research organizations in the world is a major career shift and ...
With Aduro contributing a drug and most of the money to the combined company, its shareholders will emerge with a 50% stake in Chinook. https://t.co/seFkEdAwZh
OpenAduro, Chinook ink merger to take renal drug into phase 3
Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million to take an ex-AbbVie drug through phase 3.
RT @FierceBiotech: While our listing focuses on the largest companies with the deepest pockets, it’s worth noting that Big Pharma contributed less than half of the 2019 spending tally https://t.co/rxLZXYG5fu
OpenThe top 10 pharma R&D budgets in 2019
In 2019, the top 10 pharmaceutical R&D spenders collectively ploughed around $82 billion into their search for new drugs, diagnostics and vaccines, around $4 billion more than the previous ...
.@atlasventure Raises $400M Fund to Seed Another New Set of Biotechs
- by @sarahdc
https://t.co/hgydmS3mWO
$BMY
$NVS
OpenAtlas Venture Raises $400M Fund to Seed Another New Set of Biotechs
Another venture capital firm that backs biotechs has raised a multimillion-dollar fund---money the firm, Cambridge, MA-based Atlas Venture, says it will